BioTelemetry (NASDAQ:BEAT) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

BioTelemetry (NASDAQ:BEAT) posted its quarterly earnings data on Thursday. The medical research company reported $0.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.19, MarketWatch Earnings reports. The company had revenue of $99.11 million during the quarter, compared to analyst estimates of $85.93 million. BioTelemetry had a return on equity of 17.87% and a net margin of 4.42%.

BEAT opened at $42.56 on Friday. The company has a 50-day moving average of $43.53 and a 200-day moving average of $44.90. The company has a market capitalization of $1.45 billion, a P/E ratio of 81.85, a PEG ratio of 3.03 and a beta of 1.30. BioTelemetry has a 1-year low of $27.35 and a 1-year high of $55.85. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.19 and a current ratio of 4.34.

A number of research analysts recently commented on the company. BidaskClub cut BioTelemetry from a “buy” rating to a “hold” rating in a report on Friday, June 12th. Zacks Investment Research raised BioTelemetry from a “sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, SunTrust Banks reissued a “buy” rating and issued a $58.00 target price on shares of BioTelemetry in a report on Wednesday, July 8th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $63.00.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

See Also: Equity Income

Earnings History for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with's FREE daily email newsletter.